Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
INSMED Inc Chief Legal Officer Michael Alexander Smith exercised stock options and sold shares in a pre-planned transaction. On March 30, 2026, he exercised options for 19,638 shares of common stock at exercise prices of $17.07 and $27.89 per share. The same day, he sold 19,638 shares of common stock at $150.98 per share under a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, he directly owned 51,871 shares of INSMED common stock.
INSMED Inc officer Michael Smith gave notice of a proposed sale of 19,638 common shares, with an aggregate market value of $2,964,929 and an approximate sale date of March 30, 2026. The shares are listed as acquired from the issuer through stock plan activity on March 30, 2026. The notice lists November 7, 2025 as the date of plan adoption or giving of instruction under Rule 10b5-1. It also reports five common-share sales during the prior three months, including 24,774 shares sold on February 24, 2026, for gross proceeds of $3,859,153.
Insmed Inc: The Vanguard Group filed an amendment to its Schedule 13G/A reporting beneficial ownership of 0 shares of Common Stock.
The filing explains an internal realignment effective January 12, 2026, that disaggregated certain Vanguard subsidiaries for SEC reporting; the report shows no sole or shared voting or dispositive power over Insmed shares.
Insmed Incorporated reported positive topline results from its Phase 3b ENCORE study of ARIKAYCE in patients with newly diagnosed MAC lung infection not previously treated with antibiotics. ARIKAYCE plus multidrug therapy improved Respiratory Symptom Score at Month 13 by 17.77 points versus 14.66 with placebo, a 3.11‑point advantage (p=0.0299), and achieved culture conversion by Month 6 in 87.8% of patients versus 57.0% with placebo. By Month 15, a significantly greater proportion of ARIKAYCE patients maintained durable culture conversion, and overall study completion exceeded 90% in both arms, with a safety profile consistent with known risks such as dysphonia, cough and bronchospasm. These results fulfill the U.S. FDA post‑marketing requirement, and Insmed plans a supplemental NDA in the second half of 2026 to seek U.S. label expansion and conversion of ARIKAYCE’s existing refractory indication to traditional approval, as well as a parallel submission to Japan’s PMDA.
INSMED Inc Chair and CEO William Lewis exercised stock options and sold shares in a planned transaction. On 2026-03-19, he exercised options for 10,699 shares of common stock at exercise prices of $30.46 and $17.16 per share, converting them into common shares.
That same day, he sold 10,699 shares of common stock in open-market trades at weighted average prices ranging from about $141.80 to $144.72, under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. After these transactions, he directly holds 301,185 shares, plus 233,924 shares held indirectly through the Katie Procter Dynasty Trust.
William Lewis filed a Form 144 reporting proposed sales of issuer common stock. The filing lists multiple Stock Plan Activity entries with proposed dispositions dated 03/19/2026 and earlier trade dates. Examples shown include proposed sales of 10,699 shares on 03/05/2026 and 10,699 shares on 02/19/2026. The filing lists repeated transactions under the same reporting address and identifies the market as NASDAQ.
INSMED Inc officer William Lewis reported a proposed sale of 10,699 common shares, with an aggregate market value of $1,562,311 and an approximate sale date of March 5, 2026. Merrill Lynch is named as the broker. The notice records September 4, 2025 as the date of plan adoption or giving of instruction for Rule 10b5-1 reliance, and lists a prior sale of 10,699 shares for gross proceeds of $1,615,250 on February 19, 2026.
INSMED Inc Chair and CEO William Lewis reported multiple transactions in company stock. On 2026-03-05, he exercised stock options for 6,259 and 4,440 shares of common stock through derivative conversions. He then sold a total of 10,699 common shares in open-market transactions at weighted average prices noted in the filing, effected under a Rule 10b5-1 trading plan adopted on September 4, 2025. After these trades, he held 301,185 common shares directly and 233,924 common shares indirectly through the Katie Procter Dynasty Trust as of that date.
INSMED Inc director Melvin Sharoky, MD reported a bona fide gift of common stock. On March 3, 2026, an entity associated with him transferred 100 shares of common stock as a gift transfer at a reported price of $0.0000 per share, reducing his directly held shares to 242,776.
He also reported several indirect holdings: 6,847 shares held by his spouse, 5,000 shares held by Padonia, LLC, where he is the managing member, and custodial UTMA/FL accounts holding 819, 5,423, 5,007, and 3,724 shares for named family beneficiaries.
Insmed Inc director Melvin Sharoky reported several bona fide gifts of common stock dated February 25, 2026. He gifted 1,072 shares from his direct holdings and 243 shares to each of four UTMA custodial accounts for family members. After these gifts, he continued to hold 242,876 shares directly, while indirect holdings included shares in custodial UTMA accounts, 5,000 shares held through Padonia, LLC, and 6,847 shares held by his spouse.